tirzepatide surpass cvot SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized A comparison of the effects

None of these were contradicted by anything on the brand's site - they simply weren't published in plain text where this review could confirm them

The BMI requirements for GLP-1 medications are important because these are prescription medications intended for people with clinically significant excess weight, not for cosmetic weight loss in people already at a healthy weight

i vi phng php tim tnh mch bn nn tham kho kin ca bc s da liu trc khi tim vo da v chn cc spa uy tn p dng phng php ny

When used appropriately, these medications can support meaningful weight loss and improvements in metabolic health, which are closely tied to long-term cardiovascular health and longevity